Human evidence record · Semaglutide (injectable)
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
MACE occurred in 6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90).
Quick read
Human evidence record
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Who was studied?
Adults ≥45 with established cardiovascular disease and overweight/obesity, without diabetes
How many?
n=17604
What happened?
MACE occurred in 6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90).
What stops us overclaiming?
Secondary prevention population; not generalisable to low-risk healthy adults; product discontinuation higher with semaglutide.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
MACE occurred in 6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90).
Study details
Study designRandomized, double-blind, placebo-controlled cardiovascular outcomes trial
PhasePhase 3 / outcomes
PopulationAdults ≥45 with established cardiovascular disease and overweight/obesity, without diabetes
Sample size17604
RouteSubcutaneous
Regimen / exposure2.4 mg once weekly
DurationMean exposure 34.2 months; follow-up 39.8 months
ComparatorPlacebo
Primary endpoint / questionMajor adverse cardiovascular events
Safety resultPermanent discontinuation due to adverse events 16.6% vs 8.2%.
Key limitationsSecondary prevention population; not generalisable to low-risk healthy adults; product discontinuation higher with semaglutide.
Registry / identifierNCT03574597